已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

The Most Logical Approach to Improve CAR T Cell Therapy

计算机科学 细胞疗法 计算生物学 心理学 生物 细胞 遗传学
作者
Seung-Hee Lee,Wilson W. Wong
出处
期刊:Cell systems [Elsevier BV]
卷期号:11 (5): 421-423 被引量:3
标识
DOI:10.1016/j.cels.2020.10.008
摘要

Combinational antigen recognition is the most logical way to improve the safety of cancer therapy. CAR T cells therapy, combined with synthetic biology, protein engineering, and bioinformatics, can perform advanced computations to enhance tumor targeting specificity. Combinational antigen recognition is the most logical way to improve the safety of cancer therapy. CAR T cells therapy, combined with synthetic biology, protein engineering, and bioinformatics, can perform advanced computations to enhance tumor targeting specificity. Immunotherapy, including biologic and cellular approaches, is a critical area of focus for cancer therapeutics. Of the methodologies used to “upgrade” a patient’s immune cells, one of the most promising has been chimeric antigen receptor (CAR) T cell therapy, wherein T cells are engineered to express synthetic antigen-specific receptors. A CAR consists of a ligand-binding domain fused to signaling domains from T cell receptor and costimulatory receptors. Antigen binding by the CAR triggers the signaling domain, leading to T cell activation and cell killing. Several CAR-T therapies have been approved by the FDA to treat different types of blood cancers such as acute lymphoblastic leukemia, large B cell lymphoma, and mantle cell lymphoma (Yip and Webster, 2018Yip A. Webster R.M. The market for chimeric antigen receptor T cell therapies.Nat. Rev. Drug Discov. 2018; 17: 161-162Crossref PubMed Scopus (69) Google Scholar). However, finding one or more cell-surface biomarkers that uniquely specify cancer cells—distinguishing them unequivocally from healthy cells—has restricted the applicability of these cell-based therapeutics. Given that much of the current focus in cellular immunotherapy is on enhancing their activity, the simultaneous improvement in specificity is urgently needed to expand their therapeutic window and reduce toxicity. Addressing the targeting specificity problem is the focus of recent work published in Cell Systems (Dannenfelser et al., 2020Dannenfelser R. Allen G.M. VanderSluis B. Koegel A.K. Levinson S. Stark S.R. Yao V. Tadych A. Troyanskaya O.G. Lim W.A. Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies.Cell Syst. 2020; 11 (e215): 215-228Abstract Full Text Full Text PDF PubMed Scopus (13) Google Scholar) and Science (Lajoie et al., 2020Lajoie M.J. Boyken S.E. Salter A.I. Bruffey J. Rajan A. Langan R.A. Olshefsky A. Muhunthan V. Bick M.J. Gewe M. et al.Designed protein logic to target cells with precise combinations of surface antigens.Science. 2020; 369: 1637-1643Crossref Scopus (36) Google Scholar). The solution to the issue of cell targeting specificity is obvious yet elusive. It is a common knowledge that most human cell types, including cancer cells, are best characterized by a combination of features, rather than just one “magic bullet” biomarker. Therefore, an agent that can sense and logically respond to multiple features of the cancer is the most sensible approach to develop an efficacious and safe therapy. While obvious, most existing cancer therapeutic modalities, such as small molecules and biologics, are too simplistic to carry out logic computations. Therefore, given the computation limitation in most cancer therapeutics, the only choice is to continue identifying and targeting a unique feature of cancer cells, even though we know full well that the biology is working against this approach. The concurrent advancement in cellular immunotherapy and synthetic biology, however, has drastically changed how we can target cancer cells. We are no longer constrained to target only one biomarker. Using multiple synthetic receptors, we and other have developed CAR systems or synthetic Notch receptor (synNotch) that fully activate the T cell only when two different antigens are presents on the cancer cells (AND gate) (Cho et al., 2018Cho J.H. Collins J.J. Wong W.W. Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses.Cell. 2018; 173 (e1411): 1426-1438Abstract Full Text Full Text PDF PubMed Scopus (252) Google Scholar; Kloss et al., 2013Kloss C.C. Condomines M. Cartellieri M. Bachmann M. Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells.Nat. Biotechnol. 2013; 31: 71-75Crossref PubMed Scopus (563) Google Scholar; Roybal et al., 2016Roybal K.T. Rupp L.J. Morsut L. Walker W.J. McNally K.A. Park J.S. Lim W.A. Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits.Cell. 2016; 164: 770-779Abstract Full Text Full Text PDF PubMed Scopus (474) Google Scholar). Also, an inhibitory CAR (iCAR) using the intracellular domain of the PD-1 receptor has been developed (Fedorov et al., 2013Fedorov V.D. Themeli M. Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses.Sci. Transl. Med. 2013; 5: 215ra172Crossref PubMed Scopus (421) Google Scholar). The iCAR, when combined with a conventional CAR, can form a 2-Input A AND NOT B gate. Inhibitory CARs could have a paradigm-shifting impact in cancer drug discovery because they would enable the use of “missing proteins” as a target, which is not possible by conventional therapeutics (one cannot kill cancer cells with small molecule drugs if the cancer cell is missing the target). However, these systems either require careful tuning of different receptor signaling strengths or lose the discriminatory capacity if closely related healthy cells are in close proximity (Srivastava et al., 2019Srivastava S. Salter A.I. Liggitt D. Yechan-Gunja S. Sarvothama M. Cooper K. Smythe K.S. Dudakov J.A. Pierce R.H. Rader C. et al.Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting.Cancer Cell. 2019; 35 (e488): 489-503Abstract Full Text Full Text PDF PubMed Scopus (97) Google Scholar). Lajoie, Boyken, and Salter et al. (Lajoie et al., 2020Lajoie M.J. Boyken S.E. Salter A.I. Bruffey J. Rajan A. Langan R.A. Olshefsky A. Muhunthan V. Bick M.J. Gewe M. et al.Designed protein logic to target cells with precise combinations of surface antigens.Science. 2020; 369: 1637-1643Crossref Scopus (36) Google Scholar) demonstrates an alternative AND gate and NOT gate CAR designs. Instead of using multiple receptors that integrate the signal intracellularly downstream of the receptor activation, Lajoie et al.’s system involves one receptor and performs the logic operation extracellularly through computationally designed protein logic circuits (Figure 1A). Using their previously designed Latching Orthogonal Cage–Key pRotein (LOCKR) switches (Langan et al., 2019Langan R.A. Boyken S.E. Ng A.H. Samson J.A. Dods G. Westbrook A.M. Nguyen T.H. Lajoie M.J. Chen Z. Berger S. et al.De novo design of bioactive protein switches.Nature. 2019; 572: 205-210Crossref PubMed Scopus (88) Google Scholar), they improved the system to be colocalization dependent (Co-LOCKR). The resulting co-LOCKR AND gate circuit consists of a “cage” and “key” protein, each attached to an antigen-binding domain. The cage protein also contains a peptide that can bind to CAR T cells. The peptide, however, is sequestered by a latch domain on the cage protein. The key protein binds to the cage protein, causing a conformation change and exposing the peptide for binding to and activating the CAR. The cage and key proteins are designed to not interact in solution. However, colocalized to the cell surface by antigen-binding domains favors cage-key complex formation. They also demonstrated A AND NOT B CAR by adopting a decoy design. The decoy binds to the key protein, thus preventing it from activating the cage. The Co-LOCKR design displays a remarkable logic computation capability with human immune cells. It also seems to have low off-target killing and robust activation in vitro. However, improvement is needed to translate this groundbreaking technology, especially for the NOT logic circuit. The overall T cell activity for the NOT logic CAR seems to be much lower than conventional CAR. Thus it is difficult to predict the effectiveness of the NOT gate CAR in vivo. Furthermore, both the decoy protein and its target may need to be in excess to efficiently out-compete the key from binding to the cage. Nonetheless, we anticipate that the Co-LOCKR framework can improve the combinatorial CAR T therapies by further assessing pharmacokinetics in physiological conditions and immunogenicity. With synthetic receptors that can perform logic computation, the next issue to address is determining the right combination of target antigens. Previously, Perna et al. integrated proteomic and transcriptomic data to determine the best combination of antigens for CAR T cell therapy against acute myeloid leukemia (AML) (Perna et al., 2017Perna F. Berman S.H. Soni R.K. Mansilla-Soto J. Eyquem J. Hamieh M. Hendrickson R.C. Brennan C.W. Sadelain M. Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML.Cancer Cell. 2017; 32 (e505): 506-519Abstract Full Text Full Text PDF PubMed Scopus (133) Google Scholar). Dannenfelser et al. expanded the approach to many different cancers. They imported the predicted surface genes of both tumor cells and normal tissues from RNA-seq databases with batch correction (Figure 1B). They used the Davies-Bouldin metric for a clustering-based score to measure the ratio of “within cancer/tumor antigen expression divergence” to “cancer versus tumor separation.” Proposing a score to capture off-target toxicity (precision) and inclusive on-tumor cytotoxicity (recall) when using a Boolean logic gate, they introduced a decision-tree model and presented how a combination of clinical and novel target antigens can exceed the current single target antigen approach in clinical trials. They validated their identified set of antigens for AND gate synNotch/CAR system developed by Lim group (Roybal et al., 2016Roybal K.T. Rupp L.J. Morsut L. Walker W.J. McNally K.A. Park J.S. Lim W.A. Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits.Cell. 2016; 164: 770-779Abstract Full Text Full Text PDF PubMed Scopus (474) Google Scholar) and were able to selectively kill the tumor expressing both antigens, but not when the tumor is missing one of the antigens. However, as acknowledged by the authors, their approach’s primary limitation is the limited protein expression data and incomplete normal tissue expression dataset. The availability of these data in the future will undoubtedly improve their predictions. Cancer has proven to be a formidable foe that is extraordinarily complex and remarkably relentless. We need therapeutic agents that can match the sophistication of cancer cells. CAR T cell developments, including the work by Lajoie et al. and Dannenfeser et al., are beginning to impart the intelligence and persistence into therapeutic agents required to level the playing field against cancer. While the synthetic receptor circuit designs may seem complicated, they are developed in direct response to the complex biology of many cancers. Therefore, one of our tasks ahead is to continue to invest in solutions that would turn innovative ideas outlined here into robust and effective therapies. The only way is through. This work as supported by the National Institute of Health R56 EB027729 , 1R01EB029483-01 , and Senti Biosciences . Patent applications have been filed on CAR designs (S.L, and W.W.W.). W.W.W. is a scientific co-founder, scientific advisory board member and shareholder of Senti Biosciences, and has received research support from Senti Biosciences. Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell TherapiesDannenfelser et al.Cell SystemsSeptember 10, 2020In BriefThe application of CAR T cells to solid tumors is limited by the difficulty in identifying single target antigens that adequately discriminate between tumor and normal tissue to avoid toxicity. We leverage large-scale RNA-seq databases from tumor and normal tissues to evaluate the discriminatory power of single antigens and antigen combinations. Most single antigens, including those currently under investigation as CAR targets in solid tumors, perform poorly. The addition of a second or third antigen using AND or NOT gating can significantly improve CAR T cell performance. We construct and test a pair of potential AND-gated T cells for renal cell carcinoma. A full database of all predicted high-performing antigen pairs and triplets is made available in an associated web server ( antigen.princeton.edu ). Full-Text PDF Open Archive

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
alex的应助被开放的小Q采纳,获得10
6秒前
小巧的面包完成签到 ,获得积分10
9秒前
飘逸小之发布了新的文献求助10
9秒前
陈陈潇完成签到,获得积分20
10秒前
10秒前
xr完成签到,获得积分10
11秒前
12秒前
踏实乐枫发布了新的文献求助10
15秒前
xr发布了新的文献求助10
16秒前
16秒前
17秒前
17秒前
18秒前
粗心的小鸽子完成签到,获得积分10
18秒前
跳跃的正豪完成签到,获得积分10
19秒前
yao发布了新的文献求助10
19秒前
gbh完成签到 ,获得积分20
21秒前
子皿发布了新的文献求助10
21秒前
ccccc完成签到 ,获得积分10
22秒前
moriaty发布了新的文献求助20
23秒前
自信的寄松完成签到 ,获得积分10
25秒前
专注的夜天完成签到,获得积分10
29秒前
gzghgzh完成签到,获得积分10
30秒前
菲菲完成签到 ,获得积分10
31秒前
科研通AI6.4的应助被开朗向彤采纳,获得10
32秒前
顾矜的应助被科研通管家采纳,获得10
33秒前
Owen的应助被科研通管家采纳,获得10
33秒前
彭于晏的应助被科研通管家采纳,获得10
33秒前
vc驳回了Maestro_S的应助
33秒前
桐桐的应助被科研通管家采纳,获得10
33秒前
JamesPei的应助被科研通管家采纳,获得10
33秒前
FashionBoy的应助被科研通管家采纳,获得10
34秒前
bkagyin的应助被科研通管家采纳,获得10
34秒前
34秒前
DW的应助被科研通管家采纳,获得10
34秒前
34秒前
34秒前
FashionBoy的应助被科研通管家采纳,获得10
34秒前
笙笙的应助被科研通管家采纳,获得10
34秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184917
求助须知:如何正确求助?哪些是违规求助? 9573843
关于积分的说明 21833352
捐赠科研通 7782304
什么是DOI,文献DOI怎么找? 3434429
关于科研通互助平台的介绍 2558581
邀请新用户注册赠送积分活动 2481082